Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baricitinib versus adalimumab in pediatric JIA-associated or ANA-positive anterior uveitis
2019-000119-10Phase 3Unknown
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2019
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of baricitinib and adalimumab in juvenile idiopathic arthritis-associated uveitis (JIA-U) and Chronic iridocyclitis (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary efficacy endpoint. Status: unknown.
02
Drugs
baricitinibadalimumab
03
Conditions
juvenile idiopathic arthritis-associated uveitis (JIA-U)Chronic iridocyclitis
Beyond the preview
Go deeper on 2019-000119-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000119-10.